Background
Methods
Patients and tissue
Clinicopathological data | HPyV7 | P16 | ProteinRb | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Lab ID | G. | Age | MG | Thym. type | Masaoka–Koga | Anti–AChR | IS/Ster. | IHC 2 t10 | Anti–Rb | phosRb | |
1–1 | F | 73 | + | B1/B2 | I | + | + | – | – | + | + |
1–2 | F | 75 | + | B1/B2 | I | + | + | – | – | + | + |
1–11 | F | 34 | + | B2 | I | + | – | – | ++ | + | + |
1–12 | F | 36 | + | A | I | – | + | – | – | – | – |
1–16 | F | 34 | + | A | I | + | + | – | – | + | + |
1–17 | M | 69 | + | AB | I | + | + | – | (+) | + | + |
1–18 | F | 47 | + | AB | I | + | + | – | (+) | (+) | (+) |
1–19 | M | 68 | – | AB | I | NA | NA | + | + | (+) | (+) |
1–21 | F | 38 | + | AB | I | + | – | – | – | + | – |
1–22 | M | 65 | + | AB/B2 | I | + | – | – | ++ | (+) | (+) |
1–28 | M | 38 | – | B1 | I | NA | NA | – | (+) | + | + |
1–31 | F | 82 | + | A | I | + | + | + | – | (+) | – |
1–32 | M | 47 | + | B2 | I | + | – | – | (+) | + | + |
1–34 | M | 59 | – | AB | I | NA | NA | + | + | + | + |
1–36 | F | 82 | – | AB | I | NA | NA | + | + | (+) | (+) |
1–39 | F | 78 | – | B1 | I | NA | NA | – | + | + | + |
1–43 | F | 78 | – | AB | I | NA | NA | (+) | – | + | + |
1–23 | M | 37 | + | AB | IIA | + | – | + | (+) | + | + |
1–24 | M | 68 | + | B2 | IIA | + | – | + | (+) | + | + |
1–33 | F | 43 | + | B2 | IIA | + | – | + | – | (+) | + |
1–35 | M | 45 | + | AB | IIA | + | – | + | – | + | (+) |
1–37 | M | 77 | + | AB | IIA | + | – | (+) | (+) | + | + |
1–38 | F | 80 | + | AB | IIA | + | + | – | – | – | + |
1–3 | F | 57 | + | B2/B3 | IIB | + | – | + | – | (+) | (+) |
1–5 | M | 37 | + | B3 | IIB | + | + | + | – | (+) | (+) |
1–7 | F | 79 | + | A | IIB | – | – | (+) | – | (+) | (+) |
1–8 | M | 58 | + | A/B2 | IIB | + | – | (+) | (+) | (+) | – |
1–9 | M | 64 | – | B2 | IIB | NA | NA | (+) | – | + | (+) |
1–15 | F | 53 | + | B3 | IIB | + | + | – | ++ | + | + |
1–26 | M | 65 | – | AB | IIB | NA | NA | – | + | + | – |
1–42 | F | 57 | + | AB | IIB | + | – | – | + | + | + |
1–10 | F | 73 | + | B3 | III | + | + | – | – | + | + |
1–13 | F | 54 | – | B2 | III | NA | NA | (+) | + | + | + |
1–20 | M | 64 | – | B3 | III | NA | NA | – | – | + | – |
1–41 | M | 65 | – | B3 | III | NA | NA | + | (+) | + | + |
1–4 | M | 40 | + | B2 | IVA | + | + | (+) | – | + | (+) |
1–30 | M | 37 | + | B2 | IVA | + | + | – | – | + | + |
17/37 | 19/37 | 35/37 | 31/37 | ||||||||
46 % | 51.4 % | 94.6 % | 83.8 % |
Clinicopathological data | HPyV7 | P16 | ProteinRb | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Lab ID | G. | Age | MG | Thym. type | Masaoka–Koga | Anti–AChR | IS/Ster. | IHC 2 t10 | Anti–Rb | phosRb | |
1–6 | M | 60 | – | C | III | N/A | N/A | (+) | – | + | + |
1–26 | F | 67 | – | C | IVB | N/A | N/A | – | – | + | + |
Immunohistochemistry
Statistics
Ethical approval
Results
Correlation between pRb and phosphorylated Rb expression in human thymomas and thymic carcinomas and HPyV7
Correlation between HPyV7 and p16 expression in human thymomas and thymic carcinomas
HPyV7 IHC 2 t10 | ||||
---|---|---|---|---|
Masaoka– Koga I or II | Masaoka–Koga III or IV | |||
– | + | – | + | |
P16 | ||||
– | 6 | 8 | 5 | 1 |
+ | 10 | 7 | 0 | 2 |
Double positive | 15/31 | 2/8 | ||
48.4 % | 25.0 % |